Home › NDC Lookup › RxCUI directory › RxCUI 1095712

24 HR nevirapine 400 MG Extended Release Oral Tablet — RxCUI 1095712

RxNorm drug concept · Semantic clinical drug
RxCUI 1095712 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1095712
Official name24 HR nevirapine 400 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asnevirapine 400 MG 24HR Extended Release Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)449 prescriptions · 5 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Nevirapine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Nevirapine is an antiviral drug that belongs to a class called NNRTIs — it works by blocking a key enzyme HIV needs to copy itself. But HIV is clever: if you only take one drug, th...
  • What exactly is nevirapine and why do I need to take it with other HIV medicines?
  • That first 14-day period at a once-daily lower dose is called the lead-in period, and it's actually really important — it's been shown to significantly reduce the chance of develop...
  • Why do I have to start at a lower dose for the first two weeks?
📖 Read our full Nevirapine guide →

🕸️ Concept Web — How 24 HR nevirapine 400 MG Extended Release Oral Ta... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR nevirapine 400 MG Extended Release Oral Tablet RxCUI 1095712

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Nevirapine 53654
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Viramune 224890
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Nevirapine Extended Release Oral Tablet 1095711
    • Nevirapine Oral Product 1158093
    • Nevirapine Pill 1158094
    • Nevirapine Extended Release Oral Tablet [Viramune] 1095714
    • Viramune Oral Product 1186808
    • Viramune Pill 1186809
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Nevirapine 400 MG 1095710
    • 24 HR nevirapine 400 MG Extended Release Oral Tablet [Viramune] 1095715
    • Nevirapine 400 MG [Viramune] 1095713

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Nevirapine 400 MG SCDC · 1095710
  • Nevirapine Extended Release Oral Tablet SCDF · 1095711
  • Nevirapine Oral Product SCDG · 1158093
  • Nevirapine Pill SCDG · 1158094

Brand-Name Concepts

  • 24 HR nevirapine 400 MG Extended Release Oral Tablet [Viramune] SBD · 1095715
  • Nevirapine 400 MG [Viramune] SBDC · 1095713
  • Nevirapine Extended Release Oral Tablet [Viramune] SBDF · 1095714
  • Viramune Oral Product SBDG · 1186808
  • Viramune Pill SBDG · 1186809
  • Viramune BN · 224890

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 1095712 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00378-4890-93 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-4890-... Nevirapine Mylan Pharmaceuticals Inc. 2014-10-29
33342-0238-07 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (33342-238-07) NEVIRAPINE Macleods Pharmaceuticals Limited 2017-10-07
Observed labelers: Macleods Pharmaceuticals Limited (1) · Mylan Pharmaceuticals Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$1.5450
Range $1.5450–$1.5450 · middle 50% $1.5450–$1.5450 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.